{
  "guideline": {
    "id": "PA166127639",
    "name": "Annotation of CPIC Guideline for sertraline and CYP2B6, CYP2C19",
    "source": "CPIC",
    "version": 48,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166127639",
    "relatedChemicals": [
      {
        "id": "PA451333",
        "name": "sertraline",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA123",
        "name": "cytochrome P450 family 2 subfamily B member 6",
        "symbol": "CYP2B6"
      },
      {
        "id": "PA124",
        "name": "cytochrome P450 family 2 subfamily C member 19",
        "symbol": "CYP2C19"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166300914",
      "name": "Recommendation PA166300914",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093893,
        "html": "<p>Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than CYP2C19 normal metabolizers.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.</p>\n"
      },
      "implications": [
        "CYP2B6: n/a",
        "CYP2C19: Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "No Result",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300896",
      "name": "Recommendation PA166300896",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093875,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP2B6: Normal metabolism of sertraline to less active compounds.",
        "CYP2C19: Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "Normal Metabolizer",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300901",
      "name": "Recommendation PA166300901",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093880,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP2B6: Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19: Normal metabolism"
      ],
      "lookupKey": {
        "CYP2B6": "Ultrarapid Metabolizer",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300927",
      "name": "Recommendation PA166300927",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093906,
        "html": "<p>Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.</p>\n"
      },
      "implications": [
        "CYP2B6: n/a",
        "CYP2C19: Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      ],
      "lookupKey": {
        "CYP2B6": "Indeterminate",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300892",
      "name": "Recommendation PA166300892",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093871,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2B6: n/a",
        "CYP2C19: n/a"
      ],
      "lookupKey": {
        "CYP2B6": "Indeterminate",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300945",
      "name": "Recommendation PA166300945",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093924,
        "html": "<p>Consider a lower starting dose, slower titration schedule and 25% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2B6.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>CYPC19 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.</p>\n"
      },
      "implications": [
        "CYP2B6: Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.",
        "CYP2C19: n/a"
      ],
      "lookupKey": {
        "CYP2B6": "Poor Metabolizer",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300932",
      "name": "Recommendation PA166300932",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093911,
        "html": "<p>Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.</p>\n"
      },
      "implications": [
        "CYP2B6: Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19: Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      ],
      "lookupKey": {
        "CYP2B6": "Intermediate Metabolizer",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300936",
      "name": "Recommendation PA166300936",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093915,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP2B6: Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19: n/a"
      ],
      "lookupKey": {
        "CYP2B6": "Ultrarapid Metabolizer",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300923",
      "name": "Recommendation PA166300923",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093902,
        "html": "<p>Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.</p>\n"
      },
      "implications": [
        "CYP2B6: Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19: Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      ],
      "lookupKey": {
        "CYP2B6": "Rapid Metabolizer",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300910",
      "name": "Recommendation PA166300910",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093889,
        "html": "<p>Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.</p>\n"
      },
      "implications": [
        "CYP2B6: Normal metabolism of sertraline to less active compounds.",
        "CYP2C19: Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "Normal Metabolizer",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300909",
      "name": "Recommendation PA166300909",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093888,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP2B6: Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19: Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "Rapid Metabolizer",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300940",
      "name": "Recommendation PA166300940",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093919,
        "html": "<p>Consider a lower starting dose, slower titration schedule and 25% reduction of standard maintenance dose as CYP2B6 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2B6.</p>\n"
      },
      "implications": [
        "CYP2B6: Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.",
        "CYP2C19: n/a"
      ],
      "lookupKey": {
        "CYP2B6": "Poor Metabolizer",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300931",
      "name": "Recommendation PA166300931",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093910,
        "html": "<p>Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.</p>\n"
      },
      "implications": [
        "CYP2B6: Normal metabolism of sertraline to less active compounds.",
        "CYP2C19: Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      ],
      "lookupKey": {
        "CYP2B6": "Normal Metabolizer",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300918",
      "name": "Recommendation PA166300918",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093897,
        "html": "<p>Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.</p>\n"
      },
      "implications": [
        "CYP2B6: Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19: Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "Intermediate Metabolizer",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300905",
      "name": "Recommendation PA166300905",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093884,
        "html": "<p>Consider a lower starting dose, slower titration schedule and 25% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2B6.</p>\n"
      },
      "implications": [
        "CYP2B6: Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.",
        "CYP2C19: Normal metabolism"
      ],
      "lookupKey": {
        "CYP2B6": "Poor Metabolizer",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300887",
      "name": "Recommendation PA166300887",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093866,
        "html": "<p>Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher\nmaintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19 or CYP2B6.</p>\n"
      },
      "implications": [
        "CYP2B6: Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19: Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "Ultrarapid Metabolizer",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300902",
      "name": "Recommendation PA166300902",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093881,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP2B6: Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19: Normal metabolism"
      ],
      "lookupKey": {
        "CYP2B6": "Rapid Metabolizer",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300937",
      "name": "Recommendation PA166300937",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093916,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP2B6: Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19: n/a"
      ],
      "lookupKey": {
        "CYP2B6": "Rapid Metabolizer",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300928",
      "name": "Recommendation PA166300928",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093907,
        "html": "<p>Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.</p>\n"
      },
      "implications": [
        "CYP2B6: n/a",
        "CYP2C19: Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      ],
      "lookupKey": {
        "CYP2B6": "No Result",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300915",
      "name": "Recommendation PA166300915",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093894,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP2B6: Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19: Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "Ultrarapid Metabolizer",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300897",
      "name": "Recommendation PA166300897",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093876,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP2B6: Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19: Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "Intermediate Metabolizer",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300946",
      "name": "Recommendation PA166300946",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093925,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2B6: n/a",
        "CYP2C19: n/a"
      ],
      "lookupKey": {
        "CYP2B6": "Indeterminate",
        "CYP2C19": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300933",
      "name": "Recommendation PA166300933",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093912,
        "html": "<p>Select an alternative antidepressant not primarily metabolized by CYP2C19 or CYP2B6.</p>\n"
      },
      "implications": [
        "CYP2B6: Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.",
        "CYP2C19: Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      ],
      "lookupKey": {
        "CYP2B6": "Poor Metabolizer",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300920",
      "name": "Recommendation PA166300920",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093899,
        "html": "<p>Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.</p>\n"
      },
      "implications": [
        "CYP2B6: n/a",
        "CYP2C19: Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "Indeterminate",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300924",
      "name": "Recommendation PA166300924",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093903,
        "html": "<p>Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.</p>\n"
      },
      "implications": [
        "CYP2B6: Normal metabolism of sertraline to less active compounds.",
        "CYP2C19: Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      ],
      "lookupKey": {
        "CYP2B6": "Normal Metabolizer",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300911",
      "name": "Recommendation PA166300911",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093890,
        "html": "<p>Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.</p>\n"
      },
      "implications": [
        "CYP2B6: Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19: Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "Intermediate Metabolizer",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300893",
      "name": "Recommendation PA166300893",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093872,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.</p>\n"
      },
      "implications": [
        "CYP2B6: n/a",
        "CYP2C19: Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "No Result",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300941",
      "name": "Recommendation PA166300941",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093920,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>CYPC19 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.</p>\n"
      },
      "implications": [
        "CYP2B6: Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19: n/a"
      ],
      "lookupKey": {
        "CYP2B6": "Ultrarapid Metabolizer",
        "CYP2C19": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300906",
      "name": "Recommendation PA166300906",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093885,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP2B6: n/a",
        "CYP2C19: Normal metabolism"
      ],
      "lookupKey": {
        "CYP2B6": "Indeterminate",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300888",
      "name": "Recommendation PA166300888",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093867,
        "html": "<p>Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher\nmaintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19 or CYP2B6.</p>\n"
      },
      "implications": [
        "CYP2B6: Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19: Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "Rapid Metabolizer",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300919",
      "name": "Recommendation PA166300919",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093898,
        "html": "<p>Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers</p>\n"
      },
      "implications": [
        "CYP2B6: Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.",
        "CYP2C19: Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "Poor Metabolizer",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300938",
      "name": "Recommendation PA166300938",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093917,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP2B6: Normal metabolism of sertraline to less active compounds.",
        "CYP2C19: n/a"
      ],
      "lookupKey": {
        "CYP2B6": "Normal Metabolizer",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300925",
      "name": "Recommendation PA166300925",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093904,
        "html": "<p>Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.</p>\n"
      },
      "implications": [
        "CYP2B6: Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19: Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      ],
      "lookupKey": {
        "CYP2B6": "Intermediate Metabolizer",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300916",
      "name": "Recommendation PA166300916",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093895,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP2B6: Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19: Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "Rapid Metabolizer",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300898",
      "name": "Recommendation PA166300898",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093877,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP2B6: Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.",
        "CYP2C19: Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "Poor Metabolizer",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300903",
      "name": "Recommendation PA166300903",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093882,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP2B6: Normal metabolism of sertraline to less active compounds.",
        "CYP2C19: Normal metabolism"
      ],
      "lookupKey": {
        "CYP2B6": "Normal Metabolizer",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300885",
      "name": "Recommendation PA166300885",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093864,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP2B6: n/a",
        "CYP2C19: Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "Indeterminate",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300934",
      "name": "Recommendation PA166300934",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093913,
        "html": "<p>Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.</p>\n"
      },
      "implications": [
        "CYP2B6: n/a",
        "CYP2C19: Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      ],
      "lookupKey": {
        "CYP2B6": "Indeterminate",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300921",
      "name": "Recommendation PA166300921",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093900,
        "html": "<p>Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.</p>\n"
      },
      "implications": [
        "CYP2B6: n/a",
        "CYP2C19: Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      ],
      "lookupKey": {
        "CYP2B6": "No Result",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300912",
      "name": "Recommendation PA166300912",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093891,
        "html": "<p>Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers</p>\n"
      },
      "implications": [
        "CYP2B6: Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.",
        "CYP2C19: Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "Poor Metabolizer",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300894",
      "name": "Recommendation PA166300894",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093873,
        "html": "<p>Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher\nmaintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19 or CYP2B6.</p>\n"
      },
      "implications": [
        "CYP2B6: Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19: Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "Ultrarapid Metabolizer",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300942",
      "name": "Recommendation PA166300942",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093921,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>CYPC19 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.</p>\n"
      },
      "implications": [
        "CYP2B6: Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19: n/a"
      ],
      "lookupKey": {
        "CYP2B6": "Rapid Metabolizer",
        "CYP2C19": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300929",
      "name": "Recommendation PA166300929",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093908,
        "html": "<p>Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.</p>\n"
      },
      "implications": [
        "CYP2B6: Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19: Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      ],
      "lookupKey": {
        "CYP2B6": "Ultrarapid Metabolizer",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300907",
      "name": "Recommendation PA166300907",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093886,
        "html": "<p>Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.</p>\n"
      },
      "implications": [
        "CYP2B6: n/a",
        "CYP2C19: Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "No Result",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300889",
      "name": "Recommendation PA166300889",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093868,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP2B6: Normal metabolism of sertraline to less active compounds.",
        "CYP2C19: Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "Normal Metabolizer",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300926",
      "name": "Recommendation PA166300926",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093905,
        "html": "<p>Select an alternative antidepressant not primarily metabolized by CYP2C19 or CYP2B6.</p>\n"
      },
      "implications": [
        "CYP2B6: Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.",
        "CYP2C19: Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      ],
      "lookupKey": {
        "CYP2B6": "Poor Metabolizer",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300913",
      "name": "Recommendation PA166300913",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093892,
        "html": "<p>Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.</p>\n"
      },
      "implications": [
        "CYP2B6: n/a",
        "CYP2C19: Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "Indeterminate",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300895",
      "name": "Recommendation PA166300895",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093874,
        "html": "<p>Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher\nmaintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19 or CYP2B6.</p>\n"
      },
      "implications": [
        "CYP2B6: Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19: Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "Rapid Metabolizer",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300900",
      "name": "Recommendation PA166300900",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093879,
        "html": "<p>Initiate therapy with recommended starting dose</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.</p>\n"
      },
      "implications": [
        "CYP2B6: n/a",
        "CYP2C19: Normal metabolism"
      ],
      "lookupKey": {
        "CYP2B6": "No Result",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300904",
      "name": "Recommendation PA166300904",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093883,
        "html": "<p>Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.</p>\n"
      },
      "implications": [
        "CYP2B6: Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19: Normal metabolism"
      ],
      "lookupKey": {
        "CYP2B6": "Intermediate Metabolizer",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300886",
      "name": "Recommendation PA166300886",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093865,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.</p>\n"
      },
      "implications": [
        "CYP2B6: n/a",
        "CYP2C19: Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "No Result",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300939",
      "name": "Recommendation PA166300939",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093918,
        "html": "<p>Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.</p>\n"
      },
      "implications": [
        "CYP2B6: Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19: n/a"
      ],
      "lookupKey": {
        "CYP2B6": "Intermediate Metabolizer",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300891",
      "name": "Recommendation PA166300891",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093870,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP2B6: Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.",
        "CYP2C19: Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "Poor Metabolizer",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300944",
      "name": "Recommendation PA166300944",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093923,
        "html": "<p>Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than CYP2B6 normal metabolizers.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>CYPC19 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.</p>\n"
      },
      "implications": [
        "CYP2B6: Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19: n/a"
      ],
      "lookupKey": {
        "CYP2B6": "Intermediate Metabolizer",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300935",
      "name": "Recommendation PA166300935",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093914,
        "html": "<p>No recommendation</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.</p>\n"
      },
      "implications": [
        "CYP2B6: n/a",
        "CYP2C19: n/a"
      ],
      "lookupKey": {
        "CYP2B6": "No Result",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300922",
      "name": "Recommendation PA166300922",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093901,
        "html": "<p>Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.</p>\n"
      },
      "implications": [
        "CYP2B6: Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19: Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      ],
      "lookupKey": {
        "CYP2B6": "Ultrarapid Metabolizer",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300890",
      "name": "Recommendation PA166300890",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093869,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP2B6: Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19: Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "Intermediate Metabolizer",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300943",
      "name": "Recommendation PA166300943",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093922,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>CYPC19 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.</p>\n"
      },
      "implications": [
        "CYP2B6: Normal metabolism of sertraline to less active compounds.",
        "CYP2C19: n/a"
      ],
      "lookupKey": {
        "CYP2B6": "Normal Metabolizer",
        "CYP2C19": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300930",
      "name": "Recommendation PA166300930",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093909,
        "html": "<p>Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.</p>\n"
      },
      "implications": [
        "CYP2B6: Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19: Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      ],
      "lookupKey": {
        "CYP2B6": "Rapid Metabolizer",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300917",
      "name": "Recommendation PA166300917",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093896,
        "html": "<p>Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.</p>\n"
      },
      "implications": [
        "CYP2B6: Normal metabolism of sertraline to less active compounds.",
        "CYP2C19: Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "Normal Metabolizer",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300899",
      "name": "Recommendation PA166300899",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093878,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP2B6: n/a",
        "CYP2C19: Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "Indeterminate",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300908",
      "name": "Recommendation PA166300908",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451333",
          "name": "sertraline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093887,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP2B6: Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19: Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      ],
      "lookupKey": {
        "CYP2B6": "Ultrarapid Metabolizer",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "37032427",
      "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.",
      "authors": [
        "Bousman Chad A",
        "Stevenson James M",
        "Ramsey Laura B",
        "Sangkuhl Katrin",
        "Hicks J Kevin",
        "Strawn Jeffrey R",
        "Singh Ajeet B",
        "Ruaño Gualberto",
        "Mueller Daniel J",
        "Tsermpini Evangelia Eirini",
        "Brown Jacob T",
        "Bell Gillian C",
        "Leeder J Steven",
        "Gaedigk Andrea",
        "Scott Stuart A",
        "Klein Teri E",
        "Caudle Kelly E",
        "Bishop Jeffrey R"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2023,
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/37032427"
    },
    {
      "pmid": "25974703",
      "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.",
      "authors": [
        "Hicks J K",
        "Bishop J R",
        "Sangkuhl K",
        "Müller D J",
        "Ji Y",
        "Leckband S G",
        "Leeder J S",
        "Graham R L",
        "Chiulli D L",
        "LLerena A",
        "Skaar T C",
        "Scott S A",
        "Stingl J C",
        "Klein T E",
        "Caudle K E",
        "Gaedigk A",
        "Clinical Pharmacogenetics Implementation Consortium"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2015,
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512908"
    }
  ],
  "version": "2024-02-29-20-19"
}